MT-302, a TROP2-targeting mRNA-LNP in vivo CAR therapy, is the first treatment of its kind to move into a frontline solid tumor trial Study builds on clinical experience from over 40 patients, one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback